{"id":76643,"date":"2026-08-26T12:27:10","date_gmt":"2026-08-26T04:27:10","guid":{"rendered":"https:\/\/flcube.com\/?p=76643"},"modified":"2026-08-26T12:27:11","modified_gmt":"2026-08-26T04:27:11","slug":"haisco-signs-exclusive-licensing-deal-with-sentivera-for-preclinical-autoimmune-asset-up-to-usd-1-46-billion-in-milestones","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76643","title":{"rendered":"Haisco Signs Exclusive Licensing Deal with Sentivera for Preclinical Autoimmune Asset \u2013 Up to USD 1.46 Billion in Milestones"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Haisco Pharmaceutical Group Co., Ltd.\u00a0 (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/002653:SHE\">SHE: 002653<\/a>)<\/strong> announced that it has signed an <strong>exclusive licensing agreement<\/strong> with US\u2011based <strong>Sentivera Therapeutics, Inc.<\/strong> (formerly RespiveraHealths, Inc.), granting Sentivera exclusive rights to <strong>develop, manufacture, and commercialise<\/strong> a preclinical autoimmune asset worldwide, <strong>excluding Mainland China, Hong Kong, Macau, and Taiwan<\/strong>. The deal delivers approximately <strong>USD 75.89 million in upfront consideration<\/strong> \u2014 including a <strong>17.5% equity stake<\/strong> in Sentivera \u2014 plus up to <strong>USD 1.46 billion in milestone payments and royalties<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-deal-terms\" class=\"wp-block-heading\">Deal Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Haisco (SHE: 002653)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Sentivera Therapeutics, Inc. (Delaware, US)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>Preclinical oral small\u2011molecule autoimmune\/inflammatory disease candidate<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Worldwide, excluding Mainland China, Hong Kong, Macau, and Taiwan<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>~USD 75.89M (USD 40M cash + 11,964,016 Sentivera shares worth ~USD 35.89M)<\/td><\/tr><tr><td><strong>Equity Stake<\/strong><\/td><td>17.5% of Sentivera<\/td><\/tr><tr><td><strong>Milestones &amp; Royalties<\/strong><\/td><td>Up to USD 1.46B, plus share of sublicensing revenue<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-asset-profile\" class=\"wp-block-heading\">Asset Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>Oral small\u2011molecule<\/strong> formulation, independently developed by <strong>Haisco<\/strong> with proprietary intellectual property<\/li>\n\n\n\n<li><strong>Indication Area:<\/strong> Inflammatory and autoimmune diseases<\/li>\n\n\n\n<li><strong>Preclinical Data:<\/strong> Significant efficacy and activity demonstrated in relevant animal models<\/li>\n\n\n\n<li><strong>Mechanism of Action:<\/strong> Clear and well\u2011defined, supporting differentiation within the autoimmune pipeline<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-rationale\" class=\"wp-block-heading\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Deal Structure:<\/strong> The combination of cash, equity, and milestone payments aligns Haisco&#8217;s upside with Sentivera&#8217;s long\u2011term value creation, while the <strong>sublicensing revenue share<\/strong> captures additional value from future partnering.<\/li>\n\n\n\n<li><strong>Partner Backing:<\/strong> <strong>Sentivera<\/strong>, incorporated in Delaware on 25 Nov 2025, is founded and backed by <strong>Population Health Partners, L.P. (PHP)<\/strong>, providing institutional capital and strategic support for clinical development.<\/li>\n\n\n\n<li><strong>Global Expansion:<\/strong> The transaction marks another step in <strong>Haisco&#8217;s<\/strong> strategy to monetise its proprietary pipeline through international out\u2011licensing while retaining Greater China rights.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Total Potential Value:<\/strong> Up to approximately <strong>USD 1.54 billion<\/strong> (upfront plus milestones), positioning the transaction among the larger China\u2011origin autoimmune licensing deals at the preclinical stage.<\/li>\n\n\n\n<li><strong>Investor Signal:<\/strong> The sizeable equity component (17.5% stake) gives Haisco shareholders direct exposure to the asset&#8217;s future appreciation through Sentivera.<\/li>\n\n\n\n<li><strong>Sector Context:<\/strong> Global demand for oral autoimmune therapies remains strong as payers and developers seek convenient alternatives to biologics.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding development milestones, commercialisation prospects, and financial expectations for the licensed asset. Actual results may differ due to risks including preclinical\u2011to\u2011clinical translation, regulatory outcomes, and partnering dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u4e0eSentivera\u516c\u53f8\u7b7e\u7f72\u4e00\u9879\u4e34\u5e8a\u524d\u81ea\u514d\u8d44\u4ea7\u6388\u6743\u8bb8\u53ef\u534f\u8bae\u66a8\u5173\u8054\u4ea4\u6613\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u4e0eSentivera\u516c\u53f8\u7b7e\u7f72\u4e00\u9879\u4e34\u5e8a\u524d\u81ea\u514d\u8d44\u4ea7\u6388\u6743\u8bb8\u53ef\u534f\u8bae\u66a8\u5173\u8054\u4ea4\u6613\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-5213f388-dd4e-4ab0-a469-814d5b0c9a73\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u4e0eSentivera\u516c\u53f8\u7b7e\u7f72\u4e00\u9879\u4e34\u5e8a\u524d\u81ea\u514d\u8d44\u4ea7\u6388\u6743\u8bb8\u53ef\u534f\u8bae\u66a8\u5173\u8054\u4ea4\u6613\u7684\u516c\u544a.pdf\">\u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u4e0eSentivera\u516c\u53f8\u7b7e\u7f72\u4e00\u9879\u4e34\u5e8a\u524d\u81ea\u514d\u8d44\u4ea7\u6388\u6743\u8bb8\u53ef\u534f\u8bae\u66a8\u5173\u8054\u4ea4\u6613\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u4e0eSentivera\u516c\u53f8\u7b7e\u7f72\u4e00\u9879\u4e34\u5e8a\u524d\u81ea\u514d\u8d44\u4ea7\u6388\u6743\u8bb8\u53ef\u534f\u8bae\u66a8\u5173\u8054\u4ea4\u6613\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-5213f388-dd4e-4ab0-a469-814d5b0c9a73\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Haisco Pharmaceutical Group Co., Ltd.\u00a0 (SHE: 002653) announced that it has signed an exclusive licensing&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[65,139,4909,929],"class_list":["post-76643","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-auto-immune","tag-haisco-pharmaceutical","tag-sentivera-therapeutics","tag-she-002653"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Haisco Signs Exclusive Licensing Deal with Sentivera for Preclinical Autoimmune Asset \u2013 Up to USD 1.46 Billion in Milestones - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Haisco Pharmaceutical Group Co., Ltd.\u00a0 (SHE: 002653) announced that it has signed an exclusive licensing agreement with US\u2011based Sentivera Therapeutics, Inc. (formerly RespiveraHealths, Inc.), granting Sentivera exclusive rights to develop, manufacture, and commercialise a preclinical autoimmune asset worldwide, excluding Mainland China, Hong Kong, Macau, and Taiwan. The deal delivers approximately USD 75.89 million in upfront consideration \u2014 including a 17.5% equity stake in Sentivera \u2014 plus up to USD 1.46 billion in milestone payments and royalties.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=76643\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Haisco Signs Exclusive Licensing Deal with Sentivera for Preclinical Autoimmune Asset \u2013 Up to USD 1.46 Billion in Milestones\" \/>\n<meta property=\"og:description\" content=\"Haisco Pharmaceutical Group Co., Ltd.\u00a0 (SHE: 002653) announced that it has signed an exclusive licensing agreement with US\u2011based Sentivera Therapeutics, Inc. (formerly RespiveraHealths, Inc.), granting Sentivera exclusive rights to develop, manufacture, and commercialise a preclinical autoimmune asset worldwide, excluding Mainland China, Hong Kong, Macau, and Taiwan. The deal delivers approximately USD 75.89 million in upfront consideration \u2014 including a 17.5% equity stake in Sentivera \u2014 plus up to USD 1.46 billion in milestone payments and royalties.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=76643\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-26T04:27:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-26T04:27:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76643#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76643\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Haisco Signs Exclusive Licensing Deal with Sentivera for Preclinical Autoimmune Asset \u2013 Up to USD 1.46 Billion in Milestones\",\"datePublished\":\"2026-08-26T04:27:10+00:00\",\"dateModified\":\"2026-08-26T04:27:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76643\"},\"wordCount\":393,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Haisco Pharmaceutical\",\"Sentivera Therapeutics\",\"SHE: 002653\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76643#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76643\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=76643\",\"name\":\"Haisco Signs Exclusive Licensing Deal with Sentivera for Preclinical Autoimmune Asset \u2013 Up to USD 1.46 Billion in Milestones - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-26T04:27:10+00:00\",\"dateModified\":\"2026-08-26T04:27:11+00:00\",\"description\":\"Haisco Pharmaceutical Group Co., Ltd.\u00a0 (SHE: 002653) announced that it has signed an exclusive licensing agreement with US\u2011based Sentivera Therapeutics, Inc. (formerly RespiveraHealths, Inc.), granting Sentivera exclusive rights to develop, manufacture, and commercialise a preclinical autoimmune asset worldwide, excluding Mainland China, Hong Kong, Macau, and Taiwan. The deal delivers approximately USD 75.89 million in upfront consideration \u2014 including a 17.5% equity stake in Sentivera \u2014 plus up to USD 1.46 billion in milestone payments and royalties.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76643#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76643\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76643#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Haisco Signs Exclusive Licensing Deal with Sentivera for Preclinical Autoimmune Asset \u2013 Up to USD 1.46 Billion in Milestones\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Haisco Signs Exclusive Licensing Deal with Sentivera for Preclinical Autoimmune Asset \u2013 Up to USD 1.46 Billion in Milestones - Insight, China&#039;s Pharmaceutical Industry","description":"Haisco Pharmaceutical Group Co., Ltd.\u00a0 (SHE: 002653) announced that it has signed an exclusive licensing agreement with US\u2011based Sentivera Therapeutics, Inc. (formerly RespiveraHealths, Inc.), granting Sentivera exclusive rights to develop, manufacture, and commercialise a preclinical autoimmune asset worldwide, excluding Mainland China, Hong Kong, Macau, and Taiwan. The deal delivers approximately USD 75.89 million in upfront consideration \u2014 including a 17.5% equity stake in Sentivera \u2014 plus up to USD 1.46 billion in milestone payments and royalties.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=76643","og_locale":"en_US","og_type":"article","og_title":"Haisco Signs Exclusive Licensing Deal with Sentivera for Preclinical Autoimmune Asset \u2013 Up to USD 1.46 Billion in Milestones","og_description":"Haisco Pharmaceutical Group Co., Ltd.\u00a0 (SHE: 002653) announced that it has signed an exclusive licensing agreement with US\u2011based Sentivera Therapeutics, Inc. (formerly RespiveraHealths, Inc.), granting Sentivera exclusive rights to develop, manufacture, and commercialise a preclinical autoimmune asset worldwide, excluding Mainland China, Hong Kong, Macau, and Taiwan. The deal delivers approximately USD 75.89 million in upfront consideration \u2014 including a 17.5% equity stake in Sentivera \u2014 plus up to USD 1.46 billion in milestone payments and royalties.","og_url":"https:\/\/flcube.com\/?p=76643","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-26T04:27:10+00:00","article_modified_time":"2026-08-26T04:27:11+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=76643#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=76643"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Haisco Signs Exclusive Licensing Deal with Sentivera for Preclinical Autoimmune Asset \u2013 Up to USD 1.46 Billion in Milestones","datePublished":"2026-08-26T04:27:10+00:00","dateModified":"2026-08-26T04:27:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=76643"},"wordCount":393,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Haisco Pharmaceutical","Sentivera Therapeutics","SHE: 002653"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=76643#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=76643","url":"https:\/\/flcube.com\/?p=76643","name":"Haisco Signs Exclusive Licensing Deal with Sentivera for Preclinical Autoimmune Asset \u2013 Up to USD 1.46 Billion in Milestones - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-26T04:27:10+00:00","dateModified":"2026-08-26T04:27:11+00:00","description":"Haisco Pharmaceutical Group Co., Ltd.\u00a0 (SHE: 002653) announced that it has signed an exclusive licensing agreement with US\u2011based Sentivera Therapeutics, Inc. (formerly RespiveraHealths, Inc.), granting Sentivera exclusive rights to develop, manufacture, and commercialise a preclinical autoimmune asset worldwide, excluding Mainland China, Hong Kong, Macau, and Taiwan. The deal delivers approximately USD 75.89 million in upfront consideration \u2014 including a 17.5% equity stake in Sentivera \u2014 plus up to USD 1.46 billion in milestone payments and royalties.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=76643#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=76643"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=76643#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Haisco Signs Exclusive Licensing Deal with Sentivera for Preclinical Autoimmune Asset \u2013 Up to USD 1.46 Billion in Milestones"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76643","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=76643"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76643\/revisions"}],"predecessor-version":[{"id":76645,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76643\/revisions\/76645"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=76643"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=76643"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=76643"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}